IDEAS home Printed from https://ideas.repec.org/p/pra/mprapa/79481.html
   My bibliography  Save this paper

The savings from the 2016-2020 Framework Agreement on the Supply and Pricing of Medicines in Ireland: which counterfactual?

Author

Listed:
  • Gorecki, Paul

Abstract

The Minister for Health claims savings of €600 million due to the 2016-2020 framework agreement (the Agreement) with the Irish Pharmaceutical Healthcare Association. But relative to what? No agreement. That seems implausible since such State/industry agreements have been in operation continuously since 1969. Furthermore the State has powers to set medicine prices under the Health (Pricing and Supply of Medical Goods) Act 2013? Agreed, but what would be a more appropriate counterfactual? The status quo: replicating the 2012-2015 agreement and extending its length for one year. That seems a sensible credible alternative. But what would the savings be if the status quo is the counterfactual? €290 million. Wow, less than half the Minister’s estimate. But won’t that make the Health Service Executive (HSE)’s task in deciding which new high cost medicines to fund much harder? Yes. Perhaps the HSE should set out guidance as to when a new medicine will be funded, with, for example, an upper cost-effectiveness limit. But surely the methodology and assumptions underlying the Minister’s claimed savings are published, as part of a transparent, open evidenced based policy? Afraid not. Why? Good question. This paper attempts, albeit partially, to fill the void in the analytics.

Suggested Citation

  • Gorecki, Paul, 2017. "The savings from the 2016-2020 Framework Agreement on the Supply and Pricing of Medicines in Ireland: which counterfactual?," MPRA Paper 79481, University Library of Munich, Germany.
  • Handle: RePEc:pra:mprapa:79481
    as

    Download full text from publisher

    File URL: https://mpra.ub.uni-muenchen.de/79481/1/MPRA_paper_79481.pdf
    File Function: original version
    Download Restriction: no

    References listed on IDEAS

    as
    1. James O’Mahony & Diarmuid Coughlan, 2016. "The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System?," PharmacoEconomics, Springer, vol. 34(1), pages 5-11, January.
    2. Connolly, Sheelah & Wren, Maev-Ann, 2016. "The 2011 proposal for Universal Health Insurance in Ireland: Potential implications for healthcare expenditure," Health Policy, Elsevier, vol. 120(7), pages 790-796.
    3. Paul K. Gorecki, 2011. "Economic Regulation: Recentralisation of Power or Improved Quality of Regulation?," The Economic and Social Review, Economic and Social Studies, vol. 42(2), pages 177-211.
    4. James F. O’Mahony & Diarmuid Coughlan, 2016. "The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System?," PharmacoEconomics, Springer, vol. 34(1), pages 5-11, January.
    5. Gorecki, Paul K. & Nolan, Anne & Brick, Aoife & Lyons, Seán, 2012. "Pharmaceuticals Delivery in Ireland. Getting a Bigger Bang for the Buck," Research Series, Economic and Social Research Institute (ESRI), number RS24.
    Full references (including those not matched with items on IDEAS)

    More about this item

    Keywords

    medicine prices; government/pharmaceutical industry agreements; savings.;

    JEL classification:

    • H51 - Public Economics - - National Government Expenditures and Related Policies - - - Government Expenditures and Health
    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:pra:mprapa:79481. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Joachim Winter). General contact details of provider: http://edirc.repec.org/data/vfmunde.html .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.